ANTONIO RAFAEL
ANTELA LOPEZ
Profesor contratado doutor
Hospital General Universitario de Elche
Elche, EspañaPublicacións en colaboración con investigadores/as de Hospital General Universitario de Elche (28)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy
Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 149-154
2019
-
Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505
-
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
The Lancet, Vol. 393, Núm. 10189, pp. 2428-2438
2018
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 6, pp. 377-383
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Oxidative stress predicts All-Cause mortality in HIV-Infected patients
PLoS ONE, Vol. 11, Núm. 4
-
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: A randomized trial
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 5, pp. 1346-1351
2015
-
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial
Clinical Infectious Diseases, Vol. 60, Núm. 5, pp. 811-820
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences
Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095
2014
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
AIDS, Vol. 28, Núm. 16, pp. 2461-2473